Loracarbef versus cefaclor in the treatment of urinary tract infections in women
Antimicrobial Agents & Chemotherapy. 1991; 35(4): 750-752.
In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women
Cefaclor [Therapeutic Use] [Adverse Effects]; Cephalosporins [Therapeutic Use] [Adverse Effects]; Urinary Tract Infections [Drug Therapy] [Microbiology]; Double-Blind Method; Support,Non-U.S Gov't
RCT
Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32610-0296
